Adicet Bio Inc

ACET

Company Profile

  • Business description

    Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.

  • Contact

    131 Dartmouth Street
    3rd Floor
    BostonMA02116
    USA

    T: +1 650 503-9095

    E: [email protected]

    https://www.adicetbio.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    152

Stocks News & Analysis

stocks

Overvalued ASX mining giant

Solid start to 2026 but shares overvalued.
stocks

Going into earnings, is Microsoft stock a buy, a sell, or fairly valued?

With recent structural changes and strong Azure performance, here’s what we think of Microsoft stock.
stocks

Tesla earnings: Shares fall as market focuses on uncertainty in near term

Are shares overpriced despite the fall?

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,317.2026.50-0.28%
CAC 408,225.630.15-0.00%
DAX 4024,239.8932.100.13%
Dow JONES (US)47,238.57503.961.08%
FTSE 1009,645.6267.050.70%
HKSE26,160.15192.170.74%
NASDAQ23,231.47289.671.26%
Nikkei 22549,299.65658.041.35%
NZX 50 Index13,391.5914.490.11%
S&P 5006,797.8359.390.88%
S&P/ASX 2009,019.0025.20-0.28%
SSE Composite Index3,950.3127.900.71%

Market Movers